Tom Hale
Tom Hale is the CEO and board member of ŌURA, maker of the Oura Ring health wearable. He joined ŌURA in 2022 after senior leadership roles at Momentive, HomeAway, Linden Lab, Adobe, and Macromedia, and he is publicly associated with Oura’s work in AI-powered health insights, wearable biometrics, and proactive health monitoring.
Starship V3 Scrub Delays SpaceX’s IPO-Timed Reuse Test
Bloomberg Technology framed the day’s tech news around a common test: whether ambitious hardware and AI claims can be backed by execution. Ed Ludlow and guests treated SpaceX’s scrubbed Starship V3 launch as more than a minor delay, because the vehicle is central to SpaceX’s payload, reuse and IPO story, while Lenovo CFO Winston Cheng argued that the company’s AI growth rests on both devices and infrastructure despite component constraints. The program also contrasted Zoom’s usage-based AI pitch with Bloomberg reporting that some Salesforce agentic AI demonstrations remain ahead of real customer deployment.
Cerebras Raises $5.55 Billion as AI Infrastructure Demand Lifts Tech Markets
Cerebras raised $5.55bn in the year’s largest US IPO while Cisco shares jumped on a higher hyperscaler-orders forecast, putting both a new AI compute listing and an incumbent networking supplier in the market’s AI infrastructure trade. Cerebras CEO Andrew Feldman argued that the company’s wafer-scale systems, OpenAI deal and AWS engagement show it can become a major compute supplier; Bloomberg reporters pressed the harder question of how much of today’s AI infrastructure demand will turn into broad, durable revenue.
Oura Seeks Clinical Validation for Longer-Term AI Health Prediction
Oura chief executive Tom Hale told Bloomberg Technology that the company’s AI work is not a new response to the current market cycle but an extension of years of prediction work in wearables. His argument is that Oura can move from near-term wellness signals, such as illness or menstrual-cycle alerts, toward longer-range health guidance, provided the science and regulatory validation support it. Hale said the company is still stopping short of diagnosis while it works with the FDA, including on blood-pressure submissions, and framed Oura’s hardware as an advantage in an AI market where software is easier to copy or generate.